Please login to the form below

Not currently logged in
Email:
Password:

NICE

This page shows the latest NICE news and features for those working in and with pharma, biotech and healthcare.

NICE set to reject wider use of Eisai’s breast cancer drug Halaven

NICE set to reject wider use of Eisai’s breast cancer drug Halaven

NICE set to reject wider use of Eisai’ s breast cancer drug Halaven. ... NICE agreed last year that Halaven should be made available on the NHS as a third-line option after two prior rounds of chemotherapy.

Latest news

More from news
Approximately 327 fully matching, plus 826 partially matching documents found.

Latest Intelligence

  • Pulling together Pulling together

    NICE and pharma. Also high on the agenda at the event was NICE’s approach to appraising new medicines. ... The NHS is interested in managing access, not in blocking it, ”he said, adding that NICE and pharma were “in the same business”.

  • Positive disruption in business intelligence Positive disruption in business intelligence

    Take the recent recommendation by NICE, the UK’s drug-spending policymaker, of Kadcyla, the breast cancer treatment launched by Roche. ... In December 2016, NICE issued draft guidance indicating Kadcyla was too expensive for routine funding on the NHS.

  • The patient’s world is ‘messy’ The patient’s world is ‘messy’

    Yet often the insights about patients can still be considered ‘nice to have’rather than a ‘must have’. ... It may undermine the clinician’s nice, linear view of the journey and present a more convoluted, less logical route.

  • Macron, Merkel and May: implications of the 2017 elections for the life science industry Macron, Merkel and May: implications of the 2017 elections for the life science industry

    In April 2017, NICE and NHS England introduced affordability measures to manage the uptake of innovative treatments, including a £20m budget impact threshold for all new medicines. ... The ABPI has pursued legal action, arguing that this contravenes the

  • Proving the Strategic Value of Patients Proving the Strategic Value of Patients

    Patient insights aren’t just a ‘nice to have’, they are essential to understand the space where Pharma’s drugs ‘live’.

More from intelligence
Approximately 11 fully matching, plus 81 partially matching documents found.

Latest appointments

More from appointments
Approximately 3 fully matching, plus 12 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 4 fully matching, plus 32 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

the_other_side_of_rheumation_arthritis_thumb.jpg
THE OTHER SIDE OF … RHEUMATOID ARTHRITIS
“I harassed my GP enough to get it caught early”...
The big dilemma in international digital pharma marketing
How to get consistent international marketing while meeting local affiliates’ needs....
Why pharma content marketing campaigns should be agile
Agile pharma content marketing is simply about responding to customer needs, rather than your own whims....

Infographics